REG - Faron Pharma. Oy - Approval of Warrant Terms and Conditions

Faron Pharmaceuticals OyAnnouncement

08/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH5915Ja&default-theme=true

RNS Number : 5915J  Faron Pharmaceuticals Oy  08 April 2024

Faron Pharmaceuticals Oy

("Faron" or "Company")

 

Approval of Warrant Terms and Conditions

Company announcement, April 8, 2024 at 12:10 AM (EDT) / 7:10 AM (BST) / 9:10
AM (EEST)

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First
North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER
approach to reprogramming myeloid cells to activate anti-tumor immunity in
hematological and solid tumor microenvironments, today announces that the
Board of Directors of Faron has approved the terms and conditions of the
remaining 832,934 warrants pursuant to the terms of the warrantholder
agreement (the "Warrantholder Agreement") entered into between the Company and
IPF as announced on March 28, 2024. It was previously announced that the
maximum total number of warrants to be granted pursuant to the Warrantholder
Agreement is 1,500,000, and the Board of the Company shall cause the
registration of the remaining warrants after the Annual General Meeting 2024
of the Company, held on April 5, 2024. Each warrant entitles its holder to
subscribe for one new share in the Company.

 

Further, pursuant to the terms of the Warrantholder Agreement, the number of
warrants to be issued to IPF may be further increased upon (and subject to)
agreed adjustment events so that the total number of new shares in the Company
(issued as a result of the exercise of the increased number of warrants)
multiplied by the (adjusted) subscription price per share in any subsequent
share offering undertaken by the Company is equal to EUR 1,000,000 (minus any
amounts already paid). The Company announced on April 4, 2024, that the
Company had resolved to issue an additional 53,570 warrants to IPF based on
the placement of 3,200,298 newly issued treasury shares at the issue price of
EUR 1.50.

 

The strike price of the IPF warrants is currently EUR1.50 and will be adjusted
to any lower subsequent subscription price of shares in any future share
issue. The Company will separately publish an announcement on the issuance of
any of the additional warrants.

 

For more information please contact:

 

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com (mailto:daniel@lifesciadvisors.com)

+1 (617) 430-7576

 

ICR Consilium

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilimcomms.com (mailto:faron@consilimcomms.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About Faron Pharmaceuticals Ltd.

 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments treatments and as a monotherapy in last line solid
cancers. Further information is available at www.faron.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGGDSGUGDGSR